Cadence Pharmaceuticals Reports Second Quarter 2009 Financi...( SAN DIEGO Aug. 5 /-...)

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2009.

During the second quarter of 2009, Cadence submitted its New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. The NDA was subsequently accepted for filing and designated for Priority Review by the FDA. The FDA has issued a goal date for the NDA of November 13, 2009 under the Prescription Drug User Fee Act (PDUFA).

"We are very pleased with the FDA's decision to grant Priority Review, reflecting the unmet medical need for the treatment of pain and fever in patients who cannot take medication by mouth," said Jim Breitmeyer, Executive Vice President and Chief Medical Officer of Cadence. "We look forward to working closely with the FDA during the review process and believe that Acetavance has significant potential to enhance patient care."

Also during the second quarter of 2009, Cadence announced that Scott Byrd joined the company as Senior Vice President and Chief Commercial Officer. Mr. Byrd joined Cadence from Eli Lilly and Company and has an extensive background in sales and marketing in the acute care area. His responsibilities include sales, marketing and supply chain operations.

"Scott Byrd brings a wealth of innovative commercial and executive leadership skills to Cadence," said Ted Schroeder, President and CEO of Cadence. "His current focus is on bringing together an experienced commercial leadership team with the goal o
'/>"/>